Sam Lerman, MD
Endocrinology, Diabetes & Metabolism · Hollywood, FLNPI 1932112661
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.6%.
Across 845 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$4K
- Senseonics, Incorporated$4K
- Siemens Medical Solutions USA, Inc.$4K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- plus $10K from 54 others
Across 1,169 payments — averaging $1571.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$545K
- Senseonics, Incorporated$346K
- AbbVie$280K
- Novo Nordisk AS$268K
- Novartis$138K
- Amgen$125K
- plus $136K from 12 others
What the payments were for
- Speaking & faculty fees$10,73141%
- Travel & lodging$560%
- Food & beverage$15,64059%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVIA Chemistry XPT System$3,617
- Eversense$3,600
- t:slim X2 insulin pump$2,900
- t-slim insulin pump$600
- SOLIQUA 100/33$228
- DEXCOM CGM$216
- XARELTO$134
- INVOKANA$134
- AFREZZA$125
- Omnipod$123
- INGREZZA$119
- t:slim X2 Insulin Pump with Control-IQ$116
- Korlym$114
- Vascepa$113
- Minimed Paradigm Revel$109
How this compares
$26,478 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $296,591 |
| JardianceEmpagliflozin | 165 | $168,520 |
| MounjaroTirzepatide | 109 | $113,251 |
| FarxigaDapagliflozin Propanediol | 50 | $63,265 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $44,267 |
| JanuviaSitagliptin Phosphate | 36 | $40,436 |
| SynthroidLevothyroxine Sodium | 290 | $32,384 |
| TrulicityDulaglutide | 21 | $31,084 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $27,861 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $27,437 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $27,032 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $26,592 |
| Repatha SureclickEvolocumab | 33 | $26,105 |
| RybelsusSemaglutide | 18 | $25,902 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $24,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,173 | $333,418272 claims |
| Boehringer IngelheimJardiance | $280 | $168,520165 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,111 | $150,350144 claims |
| AstraZenecaFarxiga | $704 | $63,26550 claims |
| MerckJanuvia, Janumet | $163 | $56,11358 claims |
| AbbVieSynthroid | $468 | $32,384290 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,208 | $26,59226 claims |
| AmgenProlia | $656 | $21,61413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $265 | $4,747305 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hollywood
- Paul JellingerHollywood$159K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.